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Purpose
Criteria governing the choice between intravenous (IV)
and subcutaneous (SC) routes for immunoglobulin (Ig)
substitution are not well defined. We assessed the con-
sequences of giving the choice to the patient.
Methods
We retrospectively analyzed 143 patients with primary
immunodeficiency, followed in a single center, which
were offered the choice of IVIg or SCIg. We analyzed the
route more frequently chosen, and the consequences on
compliance. In a first cohort (n = 51, average follow up
52 months), patients already on IVIg were offered the
choice to stay on IVIg or to switch to SCIg (switch
cohort). In a second cohort (n = 92, average follow up 11
months), newly diagnosed patients were offered the
choice between IVIg and SCIg before the first injection
(new cohort).
Results
In the switch cohort, 50/51 patients chose to switch to
SCIg. Of these, 90% remained on SCIg. In the new
cohort, 44/92 patients chose SCIg, of which 95%
remained on SCIg. Among the 48 patients who chose
IVIg, 73% switched to SCIg. Compliance issues were
observed in only 10 patients.
Conclusion
Giving patients the choice of treatment modality is a safe
strategy in terms of compliance. Home-based SCIg is
much more frequently chosen than hospital-based IVIg.
Given the equal efficacy and safety between hospital-based
IVIg and home-based SCIg, we believe that all patients
should be given the choice regardless of physician’s belief
of “idealness” of the candidate.
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